¿ Alexion Pharmaceuticals Inc., of New Haven, Conn., elected to its board of directors Jerry Jackson, former executive vice president of Merck & Co., and R. Douglas Norby, executive vice president and chief financial officer of LSI Logic.
¿ Cell Genesys Inc., of Foster City, Calif., appointed Joseph Vallner executive vice president and chief operating officer.
¿ Cepheid, of Sunnyvale, Calif., appointed Nicki Bowen director of software development.
¿ ChiRex Inc., of Stamford, Conn., appointed to its scientific advisory board Andrew Myers, a professor at Harvard University.
¿ CollaGenex Pharmaceuticals Inc., of Newton, Pa., named to its board of directors Robert Black, retired president of the U.S. pharmaceuticals division of AstraZeneca Inc., and Stephen Kaplan, a principal of Oaktree Capital management LLC.
¿ Compugen, of Jamesburg, N.J., appointed Salomon Langer vice president of molecular biology and drug discovery.
¿ Credit Suisse First Boston Corp., of New York, named Todd Warnock head of U.S. healthcare for its global healthcare group.
¿ CuraGen Corp., of New Haven, Conn., named Peter Lomedico vice president of discovery research.
¿ Cytoclonal Pharmaceutics Inc., of Dallas, appointed Dorit Arad executive vice president of drug design.
¿ Dyax Corp., of Cambridge, Mass., appointed Stephen Galliker executive vice president of finance and administration and chief financial officer.
¿ Epitope Inc., of Beaverton, Ore., appointed Paul Slowey director of international sales and marketing. The company also named Charles Bergeron, chief financial officer, interim president.
¿ Genentech Inc., of South San Francisco, promoted Daniel Sulzbach to vice president, information resources.
¿ Ilex Oncology Inc., of San Antonio, Texas, named Al Jecminek vice president of business development and intellectual property counsel.
¿ InterMune Pharmaceuticals Inc., of Palo Alto, Calif., hired Nzeera Virani-Ketter as vice president of clinical research.
¿ Memory Pharmaceuticals Corp., of New York, named Philip Sussman executive vice president of corporate development.
¿ MGI Pharma Inc., of Minneapolis, appointed William C. Brown chief financial officer and secretary. Brown joined MGI as controller in 1986 and has since held positions in finance, business development and investor relations.
¿ North American Vaccine Inc., of Columbia, Md., named Russell Wilson corporate secretary and acting general counsel.
¿ Oxis Therapeutics Inc., of Portland, Ore., named to its board of directors Paul Sharpe, former vice president of neurosciences project management at SmithKline Beecham plc., of London.
¿ Point Biomedical Corp., of San Carlos, Calif., appointed Jerry Griffin president and chief executive officer. Griffin is the former executive vice president of InControl, of Redmond, Wash., and was founder and president of Griffin & Schwartz PA, of Chicago.
¿ Scirex Corp., of Horsham, Pa., named Barry Sachais vice president, clinical research, neurology and psychiatry, and John Whalen, senior vice president, clinical research and project management.
¿ Select Therapeutics Inc., of Cambridge, Mass., appointed Robert Galler as vice president of corporate development. Galler is president and chairman of the Lois Joy Galler Foundation for hemolytic uremic syndrome.
¿ Tm Bioscience Corp., of Toronto, Ontario, named Richard Lockie interim chief executive officer.
¿ Xanthon Inc., of Research Triangle Park, N.C., elected Philip Tracy, a life science venture partner of Intersouth Partners, chairman of the company¿s board of directors.
¿ Xcyte Therapies Inc., of Seattle, named Stewart Craig chief operating officer and vice president.